Cart
sales@molnova.com
Vepafestinib
CAS No. 2129515-96-2
Vepafestinib( —— )
Catalog No. M37628 CAS No. 2129515-96-2
Vepafestinib is a RET inhibitor with potential antineoplastic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 201 | In Stock |
|
| 5MG | 312 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameVepafestinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionVepafestinib is a RET inhibitor with potential antineoplastic activity.
-
DescriptionVepafestinib (TAS0953/HM06; compound 6) is a RET inhibitor (extracted from patent WO2019039439). Vepafestinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
Targetc-RET
-
Recptorc-RET
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2129515-96-2
-
Formula Weight474.55
-
Molecular FormulaC26H30N6O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (105.36 mM; Ultrasonic )
-
SMILESCOCc1ccc(NC(=O)c2c(C#CCN3CCOCC3)n(c3ncnc(N)c23)C2(C)CC2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Hayashi, Kohei, et al. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN. WO2019039439.
molnova catalog
related products
-
Pralsetinib
Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion).
-
Compound TPX-0046
Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.
-
LOXO-292
LOXO-292 (Selpercatinib, LOXO 292, LOXO292) is a potent, selective, orally available RET kinase inhibitor with potential antineoplastic activity.
